INCY vs. MTD: Incyte vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Incyte (INCY) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Incyte (INCY) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for Incyte (INCY) and Mettler-Toledo (MTD)
Profile Item	INCY	MTD
Name	Incyte Corp.	Mettler-Toledo International Inc.
Country/Region	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	24.39 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	November 4, 1993	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

INCY

MTD

GSPC

Incyte (INCY) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Incyte (INCY) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Incyte (INCY) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
Total Return (1Y)	14.06%	21.58%
Total Return (3Y, Annualized)	32.03%	19.54%
Total Return (5Y, Annualized)	12.69%	2.36%

Risk Profile

Drawdown History

INCY

MTD

GSPC

Incyte (INCY) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Incyte (INCY) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
Volatility (1Y, Annualized)	33.19%	31.70%
Beta (5Y)	0.78	1.15
Max Drawdown (5Y)	-40.50%	-43.47%
Avg. Volume (3M)	1.58M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

INCY and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
Sharpe Ratio (1Y)	0.29	0.55
Sortino Ratio (1Y)	0.46	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Incyte (INCY) earns 7.84% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Max: 109.18%
INCY: 7.84%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Incyte (INCY) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; INCY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Mettler-Toledo (MTD) at 22.25% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Max: 18.05%
INCY: 6.71%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Incyte (INCY) at 33.72% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Max: 83.12%
INCY: 33.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
ROE (TTM)	7.84%	--
ROA (TTM)	17.78%	20.09%
Net Margin (TTM)	6.71%	22.25%
Operating Margin (TTM)	33.72%	28.70%
Gross Margin (TTM)	56.02%	59.16%

Growth

Revenue Growth

Both Incyte (INCY) at 21.22% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Mettler-Toledo (MTD) at 3.88%, which is closer to a typical peer reading.

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
Revenue Growth (YoY)	21.22%	3.98%
Revenue Growth (3Y CAGR)	14.84%	0.90%
EPS Growth (YoY)	4,173.33%	3.88%
EPS Growth (3Y CAGR)	61.56%	3.06%

Financial Strength

Current Ratio (MRQ)

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Max: 25.13
Q3: 12.13
Median: 5.52
INCY: 3.84
Q1: 2.47
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Mettler-Toledo (MTD) at 26.06 is above its industry debt-to-equity ratio range.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
INCY: 0.01
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
Current Ratio (MRQ)	3.84	1.10
Debt / Equity (MRQ)	0.01	26.06
Net Debt / EBITDA	-1.88	1.58

Dividends

Dividend Yield (TTM)

Neither Incyte (INCY) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Incyte (INCY) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Max: 85.34
INCY: 61.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Incyte (INCY) at 4.06 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Max: 58.18
Q3: 25.77
Median: 7.30
INCY: 4.06
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Incyte (INCY) at 4.33 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Max: 13.53
Q3: 6.54
INCY: 4.33
Median: 3.25
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Incyte (INCY) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Incyte (INCY) and Mettler-Toledo (MTD)
Metric	INCY	MTD
P/E Ratio (TTM)	61.05	37.38
P/S Ratio (TTM)	4.06	8.16
P/B Ratio (MRQ)	4.33	442.71
Free Cash Flow Yield (TTM)	5.28%	1.97%